It is still unclear whether reduced-intensity stem cell transplantation (RIST) from an HLA-mismatched related donor is feasible for hematologic malignancies. In the current study on the use of antithymocyte globulin (ATG) in 13 patients, we focused on this issue by evaluating regimenrelated toxicities, engraftment, graft-versus-host disease (GVHD), infection, and overall survival. Our results suggest that this procedure may be acceptable for patients without a matched related donor.
|出版ステータス||Published - 2003 2月 1|
ASJC Scopus subject areas